"The RADmAb® approach accelerates blood clearance and reduces bone marrow residence time compared with standard monoclonal antibodies (mAbs), while retaining target selectivity, internalisation and retention. The RADmAb® platform is currently under pre-clinical and clinical evaluation for multiple cancer targets."
Actinium under steroids...
Early Results from Transdermal Estrogen PATCH trial - 2
New Phase 1b (NON-randomized, dose timing) trial of Lu-177-PSMA-617 + Keytruda at UCSF announced
I'm new here and just finished clinical trial.
Radiation treatment 5 days a week
